影响复发上皮卵巢癌手术疗效的临床病理因素分析

党彩玲; 阳志军; 李力

doi:10.3969/j.issn.1000-8179.2012.23.014

影响复发上皮卵巢癌手术疗效的临床病理因素分析

doi: 10.3969/j.issn.1000-8179.2012.23.014

党彩玲^{①, ②},
阳志军^①,
李力^①, ,

①.
广西医科大学附属肿瘤医院（南宁市530021）
②.
四川省内江市第二人民医院

基金项目:

广西卫生厅临床科研基金项目 Z2010153

详细信息

通讯作者:
李力 lili@gxmu.edu.cn

计量
- 文章访问数: 20
- HTML全文浏览量: 4
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2012-01-25
- 修回日期: 2012-08-28

Clinicopathological Factors Influencing the Curative Effects of Surgery for Recurrent Epithelial Ovarian Cancer

Cailing DANG^{①, ②},
Zhijun YANG^①,
Li LI^{①
, ,}

①.
Department of Gynecologic Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China
②.
The Second People's Hospital of Neijiang, Neijiang 641100, China

Funds:

the Clinical Research Foundation of the Department of Health of the Guangxi Zhuang Autonomous Region Z2010153

More Information

Corresponding author: Li LI; E-mail: lili@gxmu.edu.cn

摘要

摘要: 目的分析影响复发卵巢上皮癌手术疗效的相关临床病理因素。方法采用Logistic回归方法进行分析, 并通过多因素Logistic逐步回归分析对接受手术治疗60例复发卵巢上皮性癌患者进行影响手术疗效的临床病理因素相关分析。结果 1) 60例复发卵巢上皮癌术后平均中位生存时间为26个月(95%CI: 1 8.302~33.698), 其中肿瘤细胞减灭术满意者(残留灶≤2 cm)中位生存时间为28个月(95%CI: 25.043~30.957), 不满意者为16个月(95%CI: 13.184~18.816, P=0.002)。2)Logistic回归单因素分析显示复发数目、复发时伴有腹水、复发部位是影响手术满意效果的因素(P < 0.05);而年龄、初次手术情况、病理类型、细胞学分级、手术病理分期、初次化疗方案、复发距离末次化疗时间、复发CA125水平、最大复发病灶直径大小、术前先期化疗对手术效果无明显影响(P > 0.05)。3)Logistic逐步回归分析显示复发病灶个数、复发部位、复发后伴有腹水、年龄是影响手术满意度的主要因素。结论多个临床病理因素影响复发卵巢上皮癌手术疗效, 其中复发病灶个数、复发部位、复发后伴有腹水、年龄是影响手术满意度的主要因素。
- 上皮性卵巢癌 /
- 复发 /
- 手术疗效
Abstract: Objective This study analyzed the effects of clinical and pathological factors on surgery for recurrent epithelial ovarian cancer (EOC). Methods Univariate and multivariate step-wise logistic regression analyses were used to compare clinical and pathological factors that influenced the effects of cytoreductive surgery on 60 cases with recurrent EOC. Results The overall median survival time of the 60 patients with recurrent EOC was 26 months (95% CI: 18.302 to 33.698 months). The median survival time in the patients treated by optimal cytoreductive surgery was 28 months (95% CI: 25.043 to 30.957months). By contrast, the median survival time in the patients treated by suboptimal cytoreductive surgery was 16 months (95% CI: 13.184 to 18.816 months) (P=0.002). Univariate logistic regression analysis showed that the recurrence number, relapse with ascites, and the recurrence site are factors of the surgical effects for recurrent EOC (P < 0.05). However, no relationships were observed among the following factors: age, initial surgery, pathological type, grade of tumor ceils, FIGO (International Federation of Obstetrics and Gynecology) stage, initial chemotherapeutic program, recurrence time since the last chemotherapy, recurrent CA125 level, largest recurrence lesion, and prior chemotherapy (P > 0.053). The logistic regression revealed that the recurrence number, recurrence site, relapse with aseites, and age are significant factors that gradually influence the effects of surgery for recurrent EOC. Conclusion Multiple clinical and pathological factors will affect the results of surgery for recurrent EOC., The number and site of recurrence, as well as the age and relapse with ascites are independent risk factors.
- Epithelial ovarian carcinoma /
- Recurrence /
- Treatment efficacy of surgery

HTML全文

表 1 单因素分析显示影响手术满意度的三个因素

Table 1. Univariate analysis of three factors that influence operation satisfaction

表 2 多因素逐步回归分析显示影响手术疗效的因素

Table 2. Multiple step-wise regression analysis of factors influencing operation satisfaction

参考文献(11)

[1]	Berek JS, Hacker NF, Lagasse LD, et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer[J]. Obstet Gynecol, 1983, 61(2): 189-193.
[2]	Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma[J]. Cancer, 2006, 106(9): 1933-1939. doi: 10.1002/cncr.21845
[3]	Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome[J]. Cancer, 2007, 109(4): 685-691. doi: 10.1002/cncr.22447
[4]	Zang RY, Zhang ZY, Li ZT, et al. Effect of Cytoreductive Surgery on Survival of Patients With Recurrent Epithelial Ovarian Cancer[J]. J of Sur Oncol, 2000, 75(1): 24-30. doi: 10.1002/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L
[5]	Harter P, du Bois A, Hahmann M, et al. Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial[J]. Ann Surg Oncol, 2006, 13(12): 1702-10. doi: 10.1245/s10434-006-9058-0
[6]	Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection[J]. Br J Cancer, 2005, 28, 92(6): 1026-1032.
[7]	Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma[J]. Gynecol Oncol, 2007, 106(3): 482-487. doi: 10.1016/j.ygyno.2007.04.006
[8]	Cormio G, diVagno G, Cazzolla A, et al. Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature[J]. Eur J Obstet Gynecol Reprod Biol, 1999, 86(2): 185-188. doi: 10.1016/S0301-2115(99)00067-6
[9]	Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer[J]. Ann Oncol, 2009, 20(2): 286-293. doi: 10.1093/annonc/mdn591
[10]	GüngörM, OrtaçF, ArvasM, et al. The role of secondary cytoreductive surgery for recurrent ovarian cance[J]. Gynecol Oncol, 2005, 97(1): 74-79. doi: 10.1016/j.ygyno.2004.11.057
[11]	Karam AK, Santillan A, Bristow RE, et al. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome[J]. Gynecol Oncol, 2007, 104(2): 377-80. doi: 10.1016/j.ygyno.2006.08.037